Abeona Q1 FY26 net loss widens to $17.1 million; revenue rises to $8.7 million

Abeona Therapeutics, Inc.

Abeona Therapeutics, Inc.

ABEO

0.00
  • Abeona Therapeutics posted Q1 2026 revenue of USD 8.7 million, up USD 6.3 million from Q4 2025, as net loss widened to USD 17.1 million, or USD 0.30 per share.
  • Selling, general and administrative expense climbed to USD 19.5 million, up USD 9.7 million from a year earlier, while research and development expense dipped to USD 9.6 million from USD 9.9 million.
  • Cash, cash equivalents and short-term investments fell to USD 168.3 million at March 31 from USD 191.4 million at Dec. 31.
  • ZEVASKYN adoption increased with three patients completing treatment in Q1, one treatment to date in Q2, one biopsy in manufacturing, and six more patients expected to be biopsied in Q2.
  • Qualified treatment center network expanded to six sites with New York-Presbyterian/Columbia and Children’s Hospital of Philadelphia activated, while Abeona in-licensed PSMA-targeted engineered T-cell therapy ABO-701 and expects to file an IND and start first-in-human studies in H2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abeona Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130730PRIMZONEFULLFEED9719001) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.